Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 4/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320472 | 1.00 | LMNA (0.47) | LMNATRPV4SMN1; SMN2NPC1MAPT | |
| SCHEMBL16904329 | 0.85 | CHRNB2 (0.40) | LMNATRPV4SMN1; SMN2NPC1CHRNB2 | |
| SCHEMBL3513772 | 0.80 | MEN1 (0.46) | LMNASMN1; SMN2CHRNB2CHRNA4DRD1 | |
| SCHEMBL30454073 | 0.80 | MEN1 (0.46) | LMNASMN1; SMN2CHRNB2CHRNA4DRD1 | |
| SCHEMBL29781487 | 0.78 | TRPV4 (0.42) | LMNATRPV4SMN1; SMN2NPC1MAPT | |
| SCHEMBL21801532 | 0.78 | TRPV4 (0.42) | LMNATRPV4SMN1; SMN2NPC1MAPT | |
| SCHEMBL14862285 | 0.77 | CHRNB2 (0.43) | LMNASMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL1536481 | 0.77 | LMNA (0.45) | LMNATRPV4SMN1; SMN2NPC1MAPT | |
| SCHEMBL16586557 | 0.76 | LMNA (0.43) | LMNASMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL189173 | 0.76 | TRPV4 (0.41) | LMNATRPV4SMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| EP-4262975-B1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2025-03-05 | — | — | EP | disclosed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | disclosed |
| CN-117157291-A | Heterocyclic derivatives as P2X7 receptor antagonists | 布雷耶疗法有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2401273-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2398810-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011087776-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010135014-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135014-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010096389-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010096389-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | LMNA 2257/4885TRPV4 2577/4885SMN1; SMN2 614/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | LMNA 2789/4885TRPV4 2045/4885SMN1; SMN2 1161/4885 |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | LMNA 2789/4885TRPV4 2045/4885SMN1; SMN2 1161/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | LMNA 2679/4885TRPV4 4853/4885SMN1; SMN2 1849/4885 |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | P2RX7, P2RX3, P2RX1 | LMNA 1447/4885TRPV4 44/4885SMN1; SMN2 3229/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | LMNA 1370/4885TRPV4 57/4885SMN1; SMN2 3594/4885 |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | LMNA 3474/4885TRPV4 2170/4885SMN1; SMN2 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.